solid tumor

embryonic stem cells
Biotech

Cell therapy biotech keeps adapting, selling 4 programs for $55M

USWM plans on offering jobs to about half of Adaptimmune’s workforce. As of Dec. 31, 2024, the biotech had 506 employees.
Gabrielle Masson Jul 28, 2025 10:52am
pivot change turnaround direction walk away

Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out

Jul 24, 2025 5:00am
spray painting

BMS-backed Dispatch unveils with $216M, Carl June as cofounder

Jul 23, 2025 6:30am
MA

I-Mab buys Bridge Health for $3M to strengthen givastomig push

Jul 17, 2025 8:45am
An arrow incrementally going up stairs before pointing straight up Blue background

Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win

Jul 2, 2025 9:53am
End of road sign on street

Oncternal sells cancer assets to mystery biotech, winds down ops

Jul 1, 2025 9:38am